FDA grants priority review to Simeprevir
“This is a very important step bringing simeprevir closer to the market, making this therapy available to hepatitis C patients” comments Charlotte Edenius, EVP Development of Medivir.
PortfolioMedivir’s portfolio prioritize pharmaceuticals against infectious diseases caused by virus. |
Financial information 2013
|
Simeprevir presented via a webcast |
A fully owned subsidiary
|


